Ann: Nyrada Commences Walter Reed Traumatic Brain Injury Study, page-154

13 million market cap with 10 million in funding all the way well into phase 2 and a drug which works well above expectations, 10 years worth of research and development, first of its kind and non-GLP reassurance pre clinical studies already de risking GLP results coming up in next 4 weeks heading into human trials and Walter Reed results which we know will show the same functionality as previous pre clinical studies and exceed expectations

Peers trading 70-100 million market caps after pre clinical results just funny. Let the news flow come in